Sitavig registered in seven European countries

BioAlliance Pharma's Sitavig (aciclovir Lauriad) has been approved for the treatment of recurrent labial herpes in the following European countries: Sweden, the UK, Spain, Italy, Denmark, Finland and Norway.

The decentralised procedure, with Sweden as Reference Member State, ended with a positive opinion for these first seven countries. Each country will now issue a national marketing authorisation in the coming weeks.

BioAlliance Pharma plans to pursue the submission of the registration dossier in other European countries as soon as the first quarter of 2013.

Sitavig registered in seven European countries

BioAlliance Pharma's Sitavig (aciclovir Lauriad) has been approved for the treatment of recurrent labial herpes in the following European countries: Sweden, the UK, Spain, Italy, Denmark, Finland and Norway.

The decentralised procedure, with Sweden as Reference Member State, ended with a positive opinion for these first seven countries. Each country will now issue a national marketing authorisation in the coming weeks.

BioAlliance Pharma plans to pursue the submission of the registration dossier in other European countries as soon as the first quarter of 2013.

×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

×

REQUEST A DEMO

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.